Management of neuroendocrine tumors in children, adolescents, and young adults

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue SUPPL. 2, 2012, Pages

  Howell, Della L ^a   O'Dorisio, M Sue ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF IOWA CHILDREN S HOSPITAL   (United States)

Author keywords

adolescents; Management of neuroendocrine tumors in children; young adults

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALPHA INTERFERON; CHROMOGRANIN A; CISPLATIN; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; KI 67 ANTIGEN; NEURON SPECIFIC ENOLASE; PENTETREOTIDE IN 111; SEROTONIN; SOMATOSTATIN DERIVATIVE; SYNAPTOPHYSIN;

ADOLESCENT; ADULT; APPENDECTOMY; APPENDICEAL CARCINOID; APPENDIX CARCINOMA; BRONCHUS CARCINOID; CANCER INVASION; CANCER PREVENTION; CANCER SCREENING; CANCER STAGING; CARCINOID; CARCINOID SYNDROME; CHEMOEMBOLIZATION; CHILD; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DYSPNEA; FOLLOW UP; HEMOPTYSIS; HETEROZYGOSITY LOSS; HOARSENESS; HUMAN; LOWER ABDOMINAL PAIN; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THORAX PAIN; TUMOR VOLUME; WEIGHT REDUCTION;

ADOLESCENT; AGE FACTORS; CARCINOMA, NEUROENDOCRINE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; YOUNG ADULT;

EID: 84860296772     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31824e3885     Document Type: Review

References (45)

1. Hamilton SR, Aaltonen LAE. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press; 2000:77-82.
2. Oberg K. Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther. 2002;3:863-877. (Pubitemid 37540543)
3. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
4. Modlin I, Oberg K, Chung D, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
5. Navalkele P, O'Dorisio M, O'Dorisio TM, et al. Neuroendo-crine tumors in children and young adults: incidence, survival, and prevalence in the United States. Pancreas. 2010;29:278.
6. Corpron CA, Black CT, Herzog CE, et al. A half century of experience with carcinoid tumors in children. Am J Surg Pathol. 1995;170:606-608.
7. Brandt B III, Heintz SE, Rose EF, et al. Bronchial carcinoid tumors. Ann Thorac Surg. 1984;38:63-65. (Pubitemid 14083468)
8. Wang LT, Wilkins EW Jr, Bode HH. Bronchial carcinoid tumorsinpediatricpatients. Chest. 1993;103:1426-1428.
9. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959. (Pubitemid 36173145)
10. Modlin IM, Shapiro MD, Kidd M. An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World JSurg. 2005;29:92-101. (Pubitemid 40576497)
11. Spunt SL, Pratt CB, Rao BN, et al. Childhood carcinoid tumors: the St Jude Children's Research Hospital experience. JPediatr Surg. 2000;35:1282-1286.
12. Neves GR, Chapchap P, Sredni ST, et al. Childhood carcinoid tumors: description of a case series in a Brazilian cancer center. Sao Paulo MedJ. 2006;124:21-25.
13. Prommegger R, Obrist P, Ensinger C, et al. Retrospective evaluation of carcinoid tumors of the appendix in children. WorldJSurg. 2002;26:1489-1492. (Pubitemid 36920211)
14. Dall'Igna P, Ferrari A, Luzzatto C, et al. Carcinoid tumor of the appendix in childhood: the experience of two Italian institutions. J Pediatr Gastroenterol Nutr. 2005;40:216-219. (Pubitemid 40269745)
15. Broaddus RR, Herzog CE, Hicks MJ. Neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence. Arch Pathol Lab Med. 2003;127:1200-1203. (Pubitemid 37093272)
16. Moertel CL, Weiland LH, Telander RL. Carcinoid tumor of the appendix in the first two decades of life. J Pediatr Surg. 1990;25:1073-1075. (Pubitemid 20347097)
17. Moertel CG, Weiland LH, Nagorney DM, et al. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med. 1987;317:1699-1701. (Pubitemid 18024410)
18. Jenson RT, Norton JA. Carcinoid tumors and carcinoid syndrome. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology.Vol. 2: 6th ed. Philadelphia Pa: Lippincott Williams & Wilkins; 2001:1813-1826.
19. Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res. 1999;18:133-141. (Pubitemid 29359395)
20. Vinik AI, Woltering EA, O'Dorisio TM, et al. Neuroendocrine Tumors. A Comprehensive Guide to Diagnosis and Management. Inglewood: Inter Science Institute; 2006:11-12.
21. Thorson A, Blorck G, Bjorkman G, et al. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J. 1954;47:795-817.
22. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87:1188-1196. (Pubitemid 23110391)
23. Bhattacharyya S, Davar J, Dreyfus G, et al. Carcinoid heart disease. Circulation. 2007;116:2860-2865. (Pubitemid 350301147)
24. Travis WD, Brambilla E, Muller-Hermelink K, et al. World Health Organization (WHO). Pathology & Genetics: Tumours of the Lung, Pleura, Thymus, andHeart. Lyon: IARC Press; 2004:19-20.
25. Oberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol. 2002;14:38-45. (Pubitemid 34072962)
26. Granberg D, Wilander E, Oberg K, et al. Prognostic markers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab. 2000;85:3425-3430.
27. Wells CA, Taylor SM, Cuello AC Argentaffin and argyrophil reactions and serotonin content of endocrine tumours. J Clin Pathol. 1985;38:49-53. (Pubitemid 15156133)
28. Desai DC, O'Dorisio TM, Schirmer WJ, et al. Serum pancreastatin levels predict response to hepatic artery chemo-embolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. RegulPept. 2001;96:113-117. (Pubitemid 33788843)
29. Calhoun K, Toth-Fejel S, Cheek J, et al. Serum peptide profiles in patients with carcinoid tumors. Am J Surg Pathol. 2003; 186:28-31. (Pubitemid 36773994)
30. O'Dorisio TM, Krutzik SR, Woltering EA, et al. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behav-ior. Pancreas. 2010;39:279.
31. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hy-droxyindole acetic acid evaluation in patients with neuro-endocrine tumors. Cancer. 1999;86:858-865. (Pubitemid 29399927)
32. Khanna G, O'Dorisio SM, Menda Y, et al. Gastroentero-pancreatic neuroendocrine tumors in children and young adults. Pediatr Radiol. 2008;38:251-259. (Pubitemid 351239552)
33. Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Dig Liver Dis. 2004;36(suppl):S106-S120. (Pubitemid 41115498)
34. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518. (Pubitemid 47571404)
35. Brokx HA, Risse EK, Paul MA, et al. Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. J Thorac Cardiovasc Surg. 2007;133:973-978. (Pubitemid 46435935)
36. Oberg K, Eriksson B. The role of interferons in the manage-ment of carcinoid tumors. Acta Oncol. 1991;30:519-522.
37. Kulke MH. Clinical presentation and management of carci-noid tumors. Hematol Oncol Clin North Am. 2007;21:433-455. (Pubitemid 46843513)
38. Rickes S, Ocran KW, Gerstenhauer G, et al. Evaluation of diagnostic criteria for liver metastases of adenocarcinomas and neuroendocrine tumours at conventional ultrasound, unen-hanced power Doppler sonography and echo-enhanced ultra-sound. Dig Dis. 2004;22:81-86. (Pubitemid 39070151)
39. Mork H, Ignee A, Schuessler G, et al. Analysis of neuro-endocrine tumour metastases in the liver using contrast enhanced ultrasonography. Scand J Gastroenterol. 2007;42:652-662. (Pubitemid 46633812)
40. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003;9:261-267.
41. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer. 1993;71:2624-2630. (Pubitemid 23100501)
42. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43:610-616. (Pubitemid 34507110)
43. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl):62S-66S. (Pubitemid 47619020)
44. Van Essen M, Krenning EP, Bakker WH, et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging. 2007;34:1219-1227. (Pubitemid 47290659)
45. The North American Neuroendocrine Tumor Society (NANETS). Guidelines. Pancreas. 2010;39:705-800.